肾透明细胞癌的治疗新策略：靶向代谢重编程

doi:10.3760/cma.j.issn.1673-422X.2019.07.012

摘要/Abstract

摘要： 近十年来，世界范围内肾肿瘤的发病率呈现持续增长的趋势。肾透明细胞癌（ccRCC）是肾肿瘤的主要病理类型，预后较差。ccRCC通常伴随葡萄糖、脂肪酸、谷氨酰胺、色氨酸及精氨酸代谢网络和途径的重新编程。代谢网络和途径的重新编程使肿瘤细胞迅速增殖，在营养物耗尽和缺氧的条件下存活，并逃避免疫系统的监视。靶向代谢重编程途径的关键蛋白质或酶可以作为治疗ccRCC的新策略。

关键词: 肾肿瘤, 代谢网络和途径, 治疗

Abstract: For the last decade, the incidence of kidney neoplasms has shown an obvious rising trend in the world. The most common histopathological type of kidney neoplasms is clear cell renal cell carcinoma (ccRCC), which has a poor prognosis. ccRCC is generally accompanied by reprogramming of glucose, fatty acid, glutamine, tryptophan and arginine metabolic networks and pathways. Reprogramming of metabolic networks and pathways enables tumor cells to proliferate rapidly, survive in conditions of nutrient depletion and hypoxia, and escape surveillance by epidemic systems. New strategies have been developed to the treatment of ccRCC by targeting key proteins or enzymes involved in metabolic reprogramming pathways.

Key words: Kidney neoplasms, Metabolic networks and pathways, Therapy

谌亮，彭敏，翁一鸣，宋启斌. 肾透明细胞癌的治疗新策略：靶向代谢重编程[J]. 国际肿瘤学杂志, 2019, 46(7): 443-446.

Chen Liang, Peng Min, Weng Yiming, Song Qibin. New strategies for the treatment of clear cell renal cell carcinoma: target the metabolic reprogramming[J]. Journal of International Oncology, 2019, 46(7): 443-446.

参考文献

［1］ Sciacovelli M, Frezza C. Metabolic reprogramming and epithelialtomesenchymal transition in cancer［J］. FEBS J, 2017, 284(19): 31323144. DOI: 10.1111/febs.14090. ［2］ Hakimi AA, Reznik E, Lee CH, et al. An integrated metabolic atlas of clear cell renal cell carcinoma［J］. Cancer Cell, 2016, 29(1): 104116. DOI: 10.1016/j.ccell.2015.12.004. ［3］ Lameirinhas A, MirandaGonalves V, Henrique R, et al. The complex interplay between metabolic reprogramming and epigenetic alterations in renal cell carcinoma［J］. Genes (Basel), 2019, 10(4). pii: E264. DOI: 10.3390/genes10040264. ［4］ Tarade D, Ohh M. The HIF and other quandaries in VHL disease［J］. Oncogene, 2018, 37(2): 139147. DOI: 10.1038/onc.2017.338. ［5］ Chappell JC, Payne LB, Rathmell WK. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers［J］. J Clin Invest, 2019, 129(2): 442451. DOI: 10.1172/JCI120855. ［6］ Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma［J］. Nature, 2013, 499(7456): 4349. DOI: 10.1038/nature12222. ［7］ Wettersten HI, Hakimi AA, Morin D, et al. Gradedependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis［J］. Cancer Res, 2015, 75(12): 25412552. DOI: 10.1158/00085472.CAN141703. ［8］ Crooks DR, Linehan WM. The Warburg effect in hominis: isotoperesolved metabolism in ccRCC［J］. Nat Rev Urol, 2018, 15(12): 731732. DOI: 10.1038/s4158501801101. ［9］ Ambrosetti D, Dufies M, Dadone B, et al. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clearcell renal cell carcinoma［J］. PLoS One, 2018, 13(2): e0193477. DOI: 10.1371/journal.pone.0193477. ［10］ Courtney KD, Bezwada D, Mashimo T, et al. Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo［J］. Cell Metab, 2018, 28(5): 793800.e2. DOI: 10.1016/j.cmet.2018.07.020. ［11］ Dong B, Gao Y, Kang X, et al. SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis［J］. Oncotarget, 2016, 7(49): 8043580449. DOI: 10.18632/oncotarget.12606. ［12］ Gameiro PA, Yang, Metelo AM, et al. In vivo HIFmediated reductive carboxylation is regulated by citrate levels and sensitizes VHLdeficient cells to glutamine deprivation［J］. Cell Metab, 2013, 17(3): 372385. DOI: 10.1016/j.cmet.2013.02.002. ［13］ Shu X, Gu J, Huang M, et al. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome［J］. Carcinogenesis, 2018, 39(6): 752757. DOI: 10.1093/carcin/bgy021. ［14］ Schdel J, Grampp S, Maher ER, et al. Hypoxia, hypoxiainducible transcription factors, and renal cancer［J］. Eur Urol, 2016, 69(4): 646657. DOI: 10.1016/j.eururo.2015.08.007. ［15］ Miikkulainen P, Hgel H, Seyednasrollah F, et al. Hypoxiainducible factor (HIF)prolyl hydroxylase 3 (PHD3) maintains high HIF2A mRNA levels in clear cell renal cell carcinoma［J］. J Biol Chem, 2019, 294(10): 37603771. DOI: 10.1074/jbc.RA118.004902. ［16］ Scheuermann TH, Li Q, Ma HW, et al. Allosteric inhibition of hypoxia inducible factor2 with small molecules［J］. Nat Chem Biol, 2013, 9(4): 271276. DOI: 10.1038/nchembio.1185. ［17］ Cho H, Du X, Rizzi JP, et al. Ontarget efficacy of a HIF2α antagonist in preclinical kidney cancer models［J］. Nature, 2016, 539(7627): 107111. DOI: 10.1038/nature19795. ［18］ Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma with a HIF2 antagonist［J］. Nature, 2016, 539(7627): 112117. DOI: 10.1038/nature19796. ［19］ Wallace EM, Rizzi JP, Han G, et al. A smallmolecule antagonist of HIF2α is efficacious in preclinical models of renal cell carcinoma［J］. Cancer Res, 2016, 76(18): 54915500. DOI: 10.1158/00085472.CAN160473. ［20］ Peloton Therapeutics, Inc. A phase 1, doseescalation trial of PT2385 tablets in patients with advanced clear cell renal cell carcinoma ［EB/OL］. Clinicaltrials.gov. (20181115) ［20190401］. https://www.clinicaltrials.gov/ct2/show/NCT02293980?term=02293980&rank=1. ［21］ Lucarelli G, Rutigliano M, Sallustio F, et al. Integrated multiomics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma［J］. Aging (Albany NY), 2018, 10(12): 39573985. DOI: 10.18632/aging.101685. ［22］ Abu Aboud O, Donohoe D, Bultman S, et al. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth［J］. Am J Physiol Cell Physiol, 2015, 308(11): C890C898. DOI: 10.1152/ajpcell.00322.2014. ［23］ Shroff EH, Eberlin LS, Dang VM, et al. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism［J］. Proc Natl Acad Sci U S A, 2015, 112(21): 65396544. DOI: 10.1073/pnas.1507228112. ［24］ Abu Aboud O, Habib SL, Trott J, et al. Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for realtime imaging［J］. Cancer Res, 2017, 77(23): 67466758. DOI: 10.1158/00085472.CAN170930. ［25］ Emberley E, Bennett M, Chen J, et al. CB839, a selective glutaminase inhibitor, has antitumor activity in renal cell carcinoma and synergizes with cabozantinib and everolimus［EB/OL］. Keystone Symposia, Tumor Metabolism: Mechanisms and Targets, Whistler Canada. 2017. ［20190401］. https://www.calithera.com/wpcontent/uploads/2017/12/03.2017KeystoneposterEmberley2017.pdf. ［26］ Hoerner CR, Chen VJ, Fan AC. The ‘Achilles Heel’ of metabolism in renal cell carcinoma: glutaminase inhibition as a rational treatment strategy［J］. Kidney Cancer, 2019, 3(1): 1529. DOI: 10.3233/KCA180043. ［27］ Calithera Biosciences, Inc. Phase 2 study comparing CB839 in combination with everolimus (CBE) vs. placebo with everolimus (PboE) in patients with advanced or metastatic RCC［EB/OL］. Clinical trials.gov. (20190215) ［20190401］. https://www.clinicaltrials.gov/ct2/show/NCT03163667?term=03163667&rank=1. ［28］ Sadok I, Gamian A, Staniszewska MM. Chromatographic analysis of tryptophan metabolites［J］. J Sep Sci, 2017, 40(15): 30203045. DOI: 10.1002/jssc.201700184. ［29］ Lucarelli G, Rutigliano M, Ferro M, et al. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma［J］. Urol Oncol, 2017, 35(7): 461.e15461.e27. DOI: 10.1016/j.urolonc.2017.02.011. ［30］ Mondanelli G, Bianchi R, Pallotta MT, et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells［J］. Immunity, 2017, 46(2): 233244. DOI: 10.1016/j.immuni.2017.01.005. ［31］ Amobi A, Qian F, Lugade AA, et al. Tryptophan catabolism and cancer immunotherapy targeting IDO mediated immune suppression［J］. Adv Exp Med Biol, 2017, 1036: 129144. DOI: 10.1007/9783319675770_9. ［32］ Trott JF, Kim J, Abu Aboud O, et al. Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer［J］. Oncotarget, 2016, 7(41): 6654066557. DOI: 10.18632/oncotarget.11658. ［33］ Jochems C, Fantini M, Fernando RI, et al. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigenspecific T cells［J］. Oncotarget, 2016, 7(25): 3776237772. DOI: 10.18632/oncotarget.9326. ［34］ Sheridan C. IDO inhibitors move center stage in immunooncology［J］. Nat Biotechnol, 2015, 33(4): 321322. DOI: 10.1038/nbt0415321. ［35］ NayakKapoor A, Hao Z, Sadek R, et al. Phase Ia study of the indoleamine 2,3dioxygenase 1 (IDO1) inhibitor navoximod (GDC0919) in patients with recurrent advanced solid tumors［J］. J Immunother Cancer, 2018, 6(1): 61. DOI: 10.1186/s4042501803519. ［36］ Incyte Corporation. A study of epacadostat (INCB024360) in combination with durvalumab (MEDI4736) in subjects with selected advanced solid tumors (ECHO203)［EB/OL］. Clinical trials.gov. (20190410) ［20190401］. https://www.clinicaltrials.gov/ct2/show/NCT02318277?term=02318277&rank=1. ［37］ Jahani M, Noroznezhad F, Mansouri K. Arginine: challenges and opportunities of this twofaced molecule in cancer therapy［J］. Biomed Pharmacother, 2018, 102: 594601. DOI: 10.1016/j.biopha.2018.02.109. ［38］ Ochocki JD, Khare S, Hess M, et al. Arginase 2 suppresses renal carcinoma progression via biosynthetic cofactor pyridoxal phosphate depletion and increased polyamine toxicity［J］. Cell Metab, 2018, 27(6): 12631280.e6. DOI: 10.1016/j.cmet.2018.04.009. ［39］ Burrows N, Cane G, Robson M, et al. Hypoxiainduced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADIPEG20)［J］. Sci Rep, 2016, 6: 22950. DOI: 10.1038/srep22950. ［40］ Kremer JC, Prudner BC, Lange SES, et al. Arginine deprivation inhibits the Warburg effect and upregulates glutamine anaplerosis and serine biosynthesis in ASS1deficient cancers［J］. Cell Rep, 2017, 18(4): 9911004. DOI: 10.1016/j.celrep.2016.12.077. ［41］ Polaris Group. Study ADIPEG 20 plus pembrolizumab in advanced solid cancers［EB/OL］. Clinical trials.gov. (20180222) ［20190401］. https://www.clinicaltrials.gov/ct2/show/NCT03254732?term=03254732&rank=1.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[4]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[5]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[6]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[7]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[8]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[9]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[10]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[11]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[12]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[13]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[14]	岳红云, 张百红. 肿瘤的分化治疗[J]. 国际肿瘤学杂志, 2024, 51(2): 109-113.
[15]	姜溪, 武永存, 梁艳, 楚丽, 段颖欣, 王力军, 霍俊杰. 派安普利单抗联合化疗对晚期非小细胞肺癌患者血管生成及循环内皮细胞的影响[J]. 国际肿瘤学杂志, 2024, 51(2): 89-94.